Hyaluronic acid (HA)‐decorated imatinib‐loaded liposomes (LIP‐HA44700‐Im) are developed to target CD44 positive cells for the inhalation treatment of fibrogenic lung disorders. This evidence concerns the gene CD44 and lung disorder.